Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00651105 | Effect of LAF237 on Glucagon Secretion in Patients With Type 2 Diabetes and in Healthy Subjects | PHASE3 | COMPLETED | 63 | — | — | Feb 1, 2008 | - | Nov 18, 2016 | 2 | Germany |
| NCT00567047 | Pharmacokinetic Study of Vildagliptin in Patients With Renal Impairment | PHASE1 | COMPLETED | 96 | — | — | Jul 1, 2007 | - | Mar 25, 2009 | 6 | United States, Germany |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Vildagliptin | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: Inclusion criteria - Type-2 Diabetes Patients * Male or female patients aged 30 to 75 years with Type-2 Diabetes Mellitus (T2DM) and who are in otherwise good health * Must have been diagnosed with T2DM at least 6 months prior to screening, and whose diabetes is controlled by d...